Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2019 Financial Results on March 9, 2020
January 23 2020 - 4:05PM
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative
medicine company focused on the development, manufacture, and
commercialization of product solutions for the Advanced Wound Care
and Surgical and Sports Medicine markets, today announced that
fourth quarter and fiscal year 2019 financial results will be
reported after the market closes on Monday, March 9.
Management will host a conference call at 5:00 p.m. Eastern Time
on March 9 to discuss the results of the quarter and provide a
corporate update with a question and answer session. Those who
would like to participate may dial 866-795-3142 (409-937-8908 for
international callers) and provide access code 8742229. A live
webcast of the call will also be provided on the investor relations
section of the Company's website at
investors.organogenesis.com.
For those unable to participate, a replay of the call will be
available for two weeks at 855-859-2056 (404-537-3406 for
international callers); access code 8742229. The webcast will be
archived at investors.organogenesis.com.
About Organogenesis Holdings Inc. Organogenesis
Holdings Inc. is a leading regenerative medicine company offering a
portfolio of bioactive and acellular biomaterials products in
advanced wound care and surgical biologics, including orthopedics
and spine. Organogenesis’s comprehensive portfolio is designed to
treat a variety of patients with repair and regenerative needs. For
more information, visit www.organogenesis.com.
Investor Inquiries:
Westwicke Partners
Mike Piccinino, CFA
OrganoIR@westwicke.com
443-213-0500
Press and Media Inquiries:
Organogenesis
Marcus Girolamo
MGirolamo@organo.com
817-688-4767
Organogenesis (NASDAQ:ORGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Organogenesis (NASDAQ:ORGO)
Historical Stock Chart
From Apr 2023 to Apr 2024